Biogen will advance its tau-targeting Alzheimer’s disease drug diranersen into phase 3, even though it missed the main endpoint in a midstage trial.
Anthropic joins Gates Foundation on $200m health AI pledge
Anthropic and the Gates Foundation’s initiative will close a gap in access to AI tools between high- and lower-income countries.


